BioSpace News Archive

Expanding upon an existing contract manufacturing deal first entered into in 2018; collaboration will further enable global manufacturing of ublituximab

Enspryng is expected to be the first approved medicine applying Chugai’s proprietary recycling antibody technology and can be self-administered* subcutaneously at home every four weeks

Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, announced the initiation of the Phase 2b study of the company’s lead drug candidate, STP705, for the treatment of squamous cell skin cancer.

GeneLeap Biotech, a subsidiary of Luye Life Sciences specializing in the development of nucleic acid therapeutics, presented an e-poster entitled ‘Design and synthesis of novel GalNAc linker moieties, conjugation to antisense oligonucleotides and evaluation in mice’ at the Spring Meeting of the American Chemical Society 2021.

Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that the phase III clinical trial of proxalutamide for the treatment of male patients with mild or moderate COVID-19 symptoms in the United States has completed the first patient enrollment and dosing.

4 Squares Dentistry, the Leading Dental Hospital in Medavakkam in India, Offers Dental Treatments for Kids, Teens and Adults

Health Canada is aware of the U.S. Food and Drug Administration’s recent inspection of the Emergent BioSolutions facility in Baltimore, Maryland, which noted multiple areas of concern.

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.